CA-074 Me: Selective Cathepsin B Inhibitor for Lysosomal and Necroptosis Research

Executive Summary: CA-074 Me is a methyl ester derivative of CA-074 and a membrane-permeable, highly selective cathepsin B inhibitor (IC₅₀ = 36.3 nM in vitro) [APExBIO]. It achieves ≥95% inhibition of cathepsin B activity in cultured human fibroblasts and shows complete inhibition in the presence of reducing agents (e.g., DTT) [Liu et al., 2024]. Under reducing conditions, it partially inhibits cathepsin L (>90% inhibition after pre-incubation with DTT or GSH). CA-074 Me is widely used in research dissecting the role of lysosomal proteases in necroptosis, apoptosis, and inflammation, and it has demonstrated efficacy in animal models of TNF-α-induced liver injury [APExBIO]. This article assembles granular, verifiable facts and structured guidance for integrating CA-074 Me into advanced cell death and lysosomal signaling workflows.

Biological Rationale

Lysosomes are acidic organelles (pH 4.5–5.0) containing hydrolytic enzymes essential for cellular catabolism [Liu et al., 2024]. Cathepsin B (CTSB), a cysteine protease, is one of the most abundant mammalian lysosomal proteases and plays a pivotal role in regulated cell death, including necroptosis and apoptosis [Liu et al., 2024]. Dysregulation or permeabilization of the lysosomal membrane (LMP) causes release of cathepsins, notably CTSB, into the cytosol, where they cleave essential survival proteins and trigger cell death [Liu et al., 2024]. Chemical inhibition of CTSB, via highly selective agents such as CA-074 Me, has been shown to protect cells from necroptosis and modulate inflammation [Liu et al., 2024]. CA-074 Me thus enables targeted dissection of these pathways and supports studies into the mechanistic interplay between MLKL polymerization, lysosomal signaling, and cell death processes [CA-074 Me: Unlocking Lysosomal Protease Inhibition].

Mechanism of Action of CA-074 Me

CA-074 Me is a methyl ester derivative of the irreversible cathepsin B inhibitor CA-074. The methyl ester modification confers cell permeability, allowing effective intracellular inhibition of CTSB [APExBIO]. CA-074 Me binds selectively to the active site of cathepsin B, inhibiting its proteolytic activity with an IC₅₀ of 36.3 nM in standard in vitro assays. In cultured human gingival fibroblasts, CA-074 Me achieves ≥95% inhibition of CTSB activity. Complete inhibition is observed under reducing conditions (e.g., with 10 mM DTT, pH 5.5, 37°C, 30 min pre-incubation). Under these conditions, CA-074 Me also partially inhibits cathepsin L (CTSL), with >90% inhibition after pre-incubation with 1 mM DTT or 1 mM GSH. It exhibits negligible inhibition of other lysosomal proteases under standard assay conditions [Liu et al., 2024].

Evidence & Benchmarks

• CA-074 Me (10–50 μM) achieves ≥95% inhibition of cathepsin B in cultured human gingival fibroblasts (in vitro; 37°C, pH 5.5, 30 min) (APExBIO).
• Under reducing conditions (10 mM DTT), CA-074 Me completely inhibits CTSB and >90% of CTSL activity after 30 min pre-incubation (Liu et al., 2024).
• Chemical inhibition or knockdown of CTSB protects cells from MLKL-mediated necroptosis in human HT-29 and mouse L929 cell models (Liu et al., 2024).
• CA-074 Me attenuates TNF-α-induced liver injury in murine models, supporting a role for cathepsin B in inflammation and hepatic cell death (APExBIO).
• CA-074 Me is insoluble in water but has solubility ≥19.88 mg/mL in DMSO and ≥51.5 mg/mL in ethanol (ultrasonic treatment) (APExBIO).
• Stock solutions are stable below –20°C for short-term use; long-term storage in solution is not recommended (APExBIO).

Applications, Limits & Misconceptions

CA-074 Me is widely used in experimental models of apoptosis, necroptosis, and lysosomal function. It enables precise assessment of cathepsin signaling pathways in cell-based assays and animal models. The compound has been implemented to dissect MLKL-mediated lysosomal membrane permeabilization and its downstream effects on cell death and inflammation [Strategic Cathepsin B Inhibition]. This article extends previous coverage by providing updated, structured benchmarks and clarifying selectivity parameters.

Common Pitfalls or Misconceptions

• CA-074 Me is not active against non-cysteine proteases or unrelated lysosomal enzymes under standard assay conditions.
• Partial inhibition of cathepsin L only occurs under strongly reducing conditions; CA-074 Me is not a broad lysosomal protease inhibitor.
• The compound is insoluble in water; improper dissolution may lead to dosing errors or experimental artifacts.
• Long-term storage of CA-074 Me in solution (DMSO or ethanol) at room temperature leads to degradation; stock solutions should be freshly prepared and stored below –20°C.
• Observed protective effects in necroptosis models are CTSB-dependent and may not generalize to cell death mechanisms independent of lysosomal proteases.

Workflow Integration & Parameters

Researchers should dissolve CA-074 Me in DMSO (≥19.88 mg/mL) or ethanol (≥51.5 mg/mL with ultrasonic treatment) for stock solution preparation. Working concentrations typically range from 1–50 μM in cell culture. Stock solutions must be stored below –20°C and used within 1–2 weeks to minimize degradation. In vitro assays should specify buffer composition (e.g., 50 mM sodium acetate, pH 5.5), temperature (37°C), and pre-incubation with reducing agents (e.g., 10 mM DTT) for maximal activity profiling. For in vivo studies, dosing is determined based on animal model and delivery route, referencing established efficacy in TNF-α-induced liver injury models [APExBIO].

For advanced mechanistic studies, CA-074 Me can be integrated with MLKL polymerization assays to clarify the temporal relationship between lysosomal membrane permeabilization, cathepsin release, and cell death, as detailed in CA-074 Me: Unlocking Lysosomal Protease Inhibition (this article expands on those mechanistic insights with newly benchmarked selectivity data). For comparative analyses of inhibitor selectivity and optimization strategies, see Strategic Cathepsin B Inhibition (here, we update recommended workflows for experimental and translational settings).

Conclusion & Outlook

CA-074 Me, available from APExBIO (SKU: A8239), remains the gold-standard cell-permeable cathepsin B inhibitor for dissecting lysosomal protease function in apoptosis, necroptosis, and inflammation research. Its high selectivity, robust inhibition profile, and compatibility with established cell death models reinforce its value in mechanistic and translational workflows. Ongoing studies are expected to further elucidate the interplay between lysosomal membrane permeabilization, cathepsin signaling, and regulated cell death, with CA-074 Me as a critical tool. For further mechanistic analysis using CA-074 Me in necroptosis and inflammation, see Advanced Cathepsin B Inhibition for Lysosomal Research (this article provides updated solubility and workflow benchmarks not included in previous reviews).